Bioscience

Tucson biotech gets a nod from the NCI to develop a treatment for solid malignant tumors

August 2, 2010

By Flinn Foundation

[Source: EarthTimes] – NuvOx Pharma, LLC, a biotechnology firm based in Tucson, Arizona, received a grant from the National Cancer Institute (NCI) to fund development of its lead oxygen delivery product, NVX-108. Dr. Jennifer Johnson, Chief Operating Officer of NuvOx, said, “It’s not easy for small companies to get a ‘leg-up’ in this economic climate; thus, we are so pleased that this funding will fully support our team on a project in which we will be able to optimize and preliminarily test our product, NVX-108, against cancer.”

For more information: Tucson Biotech Gets a Nod from the National Cancer Institute to Develop a Treatment for Solid Malignant Tumors